Recruitment Initiated into Expanded Ph 2 Opaganib/Darolutamide Combo Study in Advanced Prostate Cancer July 8, 2025
Ph 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda in 1L Treatment for Advanced or Metastatic MCC initiated July 1, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
First Patient Dosed in DENALI-1 Ph 1/2 Clinical Study of A2B395 CAR T Cell Therapy for Patients with EGFR-expressing Solid Tumors July 1, 2025
First patient dosed in Ph 1/2 trial of TNG462 and daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer July 1, 2025
Second patient dosed in Ph 2 trial protocol of stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer July 1, 2025
CDR609 Announced as New T-Cell Engager Clinical Candidate Targeting LGR5 in Solid Tumors July 1, 2025
New arm (Cohort 4) initiated in SCOPE Ph 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+ June 26, 2025
IDeate-Prostate01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic CRPC June 24, 2025
Recruitment for [212Pb]VMT-α-NET Commenced in the Third Dose Escalation Cohort of Ongoing Ph 1/2a Clinical Trial June 24, 2025
First Patient Completes DLT Observation Period with No Reported DLTs in Ph 1 Trial of CER-1236 June 24, 2025
First patient dosed in DESTINY-Endometrial01 Ph 3 Trial of ENHERTU® Initiated as 1L Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer June 17, 2025
First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC) June 17, 2025
FDA Removes Partial Clinical Hold from Ph 3 Trial of IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma June 11, 2025
First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors June 10, 2025
Dose escalation completed in IAM1363-01 Ph 1/1b trial of IAM1363 in patients with HER2-altered cancers & brain mets / HER2 TKD mutation / HER2-amplified NSCLC June 10, 2025
